Efficacy, safety, and survival findings after long‐term follow‐up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.

Details

Language :

English

ISSN :

03618609

Volume :

99

Issue :

4

Database :

Complementary Index

Journal :

American Journal of Hematology

Publication Type :

Academic Journal

Accession number :

176104901

Full Text :

https://doi.org/10.1002/ajh.27245